RETROSPECTIVE STUDY ON THERAPEUTIC DRUG MONITORING OF LAMOTRIGINE IN INDIAN EPILEPTIC PATIENTS
Keywords:
Lamotrigine, Adjunctive therapy, Inter-individual variation, Drug monitoringAbstract
Objective: Antiepileptic drugs (AED) are administered either singly or in combination with other drugs. Their pharmacokinetics is influenced by drug-drug interaction & inter-individual variations. Lamotrigine (LTG) is a second order AED with similar constraints.
Hence studying the relationship between lamotrigine dosage and plasma concentration was undertaken to offer assistance in therapeutic regimen.
Methods: Pre-dose blood samples for lamotrigine estimation were obtained from 267 patients (138adults & 127children) including 2 pregnant women. Lamotrigine estimation was done by high performance liquid chromatography.
Results: In our study more children (73%) than adults (34%) were on adjunctive therapy with inhibitors (valproic acid) or inducers (phenytoin, carbamazepine, oxcarbamazepine). Irrespective of co-therapy lamotrigine level within therapeutic range with an optimal seizure control was obtained only in 76% of children and 65% adults. In case of polytherapy with valproic acid, when lamotrigine dose was maintained similar or lower than monotherapy, lamotrigine levels were 105% and 65% higher in adults and children respectively. Increased volume as observed in pregnancy had a remarkable influence on lamotrigine level. An increase in drug dose with an increase in gestation was required in both pregnant women to maintain the plasma level.
Conclusion: Inter-individual variations, co-medications and clinical conditions like pregnancy influence plasma lamotrigine level. Thus, drug monitoring is essential to obtain therapeutic efficacy for individual dose optimization.
Downloads
References
Jefferson JW. Lamotrigine in psychiatry:pharmacology and therapeutics. J CNS Spectr 2005;10(3):224-32.
Krasowski M. Therapeutic drug monitoring of the newer anti-epilepsy medications. J Pharm 2010;3(6):1909-35.
Neels H, Sierens A, Naelaerts K, Scharpe S, Hatfield G, Lambert W. Therapeutic drug monitoring of old and newer anti-epileptic drugs. J Clin Chem Lab Med 2004;42(11):1228-55.
Johannessen S, Battino D, Berry D, Bialer M, Krämer G, Tomson T et al. Therapeutic drug monitoring of the newer antiepileptic drugs. J Ther Drug Monit 2003;25(3):347-63.
Bialer M, White H. Key factors in the discovery and development of new antiepileptic drugs. J Nat Rev Drug Discov 2010;9(1):68-82.
Morris R, Black A, Harris A, Batty A, Sallustio B. Lamotrigine and therapeutic drug monitoring:retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 1998;46(6):547-51.
Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997;43(5):457-65.
Patsalos P, Berry D, Bourgeois B, Cloyd J, Glauser T, Johannessen S et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring:a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. J Epilepsia 2008;49(7):1239-76.
Keck Jr P, McElroy S. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002;63(4):3-11.
Reimers A, Brodtkorb E. Second-generation antiepileptic drugs and pregnancy:a guide for clinicians. J Expert Rev Neurother 2012;12(6):707-17.
Bartoli A, Guerrini R, Belmonte A, Alessandrì MG, Gatti G, Perucca E. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children:a prospective study with preliminary assessment of correlations with clinical response. J Ther Drug Monit1997;19(3):252-60.
Pisani F, Perucca E, Di Perri R. Clinically relevant anti-epileptic drug interactions. J Int Med Res 1990;18(1):1-15.
ClinRep® HPLC Complete Kit-Lamotrigine and Sulthiame in Plasma–RECIPE:Germany 2010;Version 2.3.
Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. J Neurology 2004;63(6):1022-6.
Pennell PB. The role of Therapeutic Drug Monitoring in Patient care. J Adv Studies in Medicine 2004;4(7C):S599-S606.
Grisotto K, Bruck I, Antoniuk S, Santos L. Association of lamotrigine and valproate in refractory epilepsies of children and adolescents. J Arq Neuropsiquiatr 2008;66(3A):477-81.
May TW, Rambeck B, Jürgens U. Serum concentrations of lamotrigine in epileptic patients:the influence of dose and comedication. J Ther Drug Monit 1996;18(5):523-31.
Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. J Clin Pharmacokinet 2006;45(4):351-63.
Yamamoto Y, Inoue Y, Matsuda K, Takahashi Y, Kagawa Y. Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients. J Biological and Pharm Bulletin 2012;35(4):487-93.
Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Effect of antiepileptic drug co medication on lamotrigine clearance. J Arch Neurol 2005;62(9):1432-6.
Armijo J, Bravo J, Cuadrado A, Herranz J. Lamotrigine serum concentration-to-dose ratio:influence of age and concomitant antiepileptic drugs and dosage implications. J Ther Drug Monit 1999;21(2):182-90.
Man S, Petersen I, Thompson M, Nazareth I. Antiepileptic drugs during pregnancy in primary care:a UK population based study. J PloS one 2012;7(12):52339.
Pennell P, Peng L, Newport D, Ritchie J, Koganti A, Holley D et al. Lamotrigine in pregnancy Clearance, therapeutic drug monitoring, and seizure frequency. J Neurology 2008;70(22 Pt 2):2130-6.
López M, Dorado P, Monroy N, Alonso ME, Jung-Cook H, MachÃn E, et al. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine. J Drug Metabol Drug Interact 2011;26(1):5-12.